Pharmaceutical - Pharmaceutical, Dermatologicals

Filter

Popular Filters

1 to 25 of 116 results

NICE gives go ahead for Xolair to treat potentially disabling skin condition

NICE gives go ahead for Xolair to treat potentially disabling skin condition

11-03-2015

The medicines cost watchdog the National Institute of Health and Care Excellence (NICE) has recommended…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

European Commission approves Actavis’ Xydalba

02-03-2015

The European Commission has granted Ireland-headquartered Actavis' subsidiary Durata Therapeutics International…

ActavisAngeliniAntibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsEuropePharmaceuticalXydalba

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

23-02-2015

A Phase IIb study of dupilumab, from Sanofi and Regeneron, has shown that the drug improved patient-reported…

DermatologicalsdupilumabPharmaceuticalRegeneronResearchSanofi

Ferrer licenses Canadian rights for ozenoxacin to Cipher Pharma

07-01-2015

Privately-held Spanish pharmaceutical company Ferrer says it has licensed commercialization rights for…

CanadaCipher PharmaceuticalsDermatologicalsFerrerLicensingOzenoxacinPharmaceutical

Leo Pharma files for US approval of first aerosol foam for psoriasis

06-01-2015

Independent Danish dermatology specialist Leo Pharma has submitted a New Drug Application to the US Food…

BetamethasonecalcipotrienecalcipotriolDermatologicalsLEO PharmaPharmaceuticalRegulationUSA

FDA approves Teva’s Granix and Galderma’s Soolantra

FDA approves Teva’s Granix and Galderma’s Soolantra

24-12-2014

The Food and Drug Administration has approved Israeli generics giant Teva Pharmaceutical Industries’…

DermatologicalsGaldermaGranixIvermectinPharmaceuticalRare diseasesRegulationSoolantraTeva Pharmaceutcal IndustriesUSA

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

15-12-2014

Swiss drug major Novartis announced that the Phase IIIb CLEAR study for Cosentyx (secukinumab) met its…

CosentyxDermatologicalsNovartisPharmaceuticalResearchSwitzerland

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

26-11-2014

USA-based Amgen, the world’s leading independent biotech firm, and Anglo-Swedish drug major AstraZeneca…

AmgenAstraZenecabrodalumabDermatologicalsPharmaceuticalResearch

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Leo Pharma reports positive results in its trial of Daivobet in psoriasis

Leo Pharma reports positive results in its trial of Daivobet in psoriasis

29-10-2014

Independent Danish dermatology specialist Leo Pharma has demonstrated significant improvement in psoriasis…

DaivobetDenmarkDermatologicalsLEO PharmaPharmaceuticalResearch

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

EADV: Celgene helps to raise awareness of psoriasis burden and presents new Otezla data

EADV: Celgene helps to raise awareness of psoriasis burden and presents new Otezla data

14-10-2014

US biotech company Celgene took a practical approach to raising awareness of psoriasis and psoriatic…

Celgene Corp.DermatologicalsEuropeHealthcareOtezlaPharmaceuticalResearchUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

10-10-2014

Swiss drug major Novartis has reported data from a Phase III trial showing consistent efficacy in clearing…

DermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Zynerba Pharmaceuticals announces CEO and president

Zynerba Pharmaceuticals announces CEO and president

02-10-2014

USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal…

BoardroomDermatologicalsPharmaceuticalUSAZynerba Pharmaceuticals

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Merck & Co out-licenses tildrakizumab to Sun Pharma

Merck & Co out-licenses tildrakizumab to Sun Pharma

17-09-2014

US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker…

DermatologicalsGlobalLicensingMerck & CoPharmaceuticalSun Pharmaceuticalstildrakizumab

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

High long-term efficacy of LEO Pharma’s Picato in actinic keratosis confirmed

04-09-2014

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers…

DermatologicalsLEO PharmaPharmaceuticalPicatoResearch

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Sandoz in deal to commercialize Anacor’s Kerydin in USA

Sandoz in deal to commercialize Anacor’s Kerydin in USA

22-07-2014

USA-based Anacor Pharmaceuticals has entered into an exclusive agreement with Sandoz, a subsidiary of…

Anacor PharmaceuticalsBusiness FinanceDermatologicalsKerydinLicensingMajorNovartisOnychomycosisPharmaceuticalPharmaceutical industryPharmaDermSandozTopical solutionUSA

LEO Pharma strikes global dermatology deal with KLOK Tech

LEO Pharma strikes global dermatology deal with KLOK Tech

16-07-2014

Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies,…

Acne vulgarisDermatologicalsGlobalKLOX TechnologiesLEO PharmaLicensingPharmaceutical

1 to 25 of 116 results

Back to top